Cyclophosphamide

News Cyclophosphamide

• immatics announces Phase II Results with its Therapeutic Cancer Vaccine IMA901 in Patients with Advanced Renal Cell Carcinoma

  immatics biotechnologies GmbH announced that results from its Phase II clinical trial with IMA901 in patients with advanced renal cell carcinoma were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Following discussions with key opinion leaders, i more

• CellCept reaches positive results in Phase III trial in Lupus Nephritis

  Vifor Pharma, the pharma business sector of the Galenica Group, and Roche announced that the maintenance phase of the Aspreva Lupus Management Study (ALMS) has successfully achieved its primary endpoint. The trial demonstrates the superiority of Roche’s CellCept (mycophenolate mofetil) versus azathi more

• Merck KGaA: Stimuvax Clinical Program Temporarily Suspended

  Merck KGaA announced that it has temporarily suspended the clinical program for Stimuvax® (BLP25 liposome vaccine) in all recruiting studies worldwide as a result of a suspected unexpected serious adverse reaction (SUSAR). This decision was taken in alignment with the U.S. Food and Drug Administrati more

Publications Cyclophosphamide

• Enhancing the sensitivity of the comet assay as a genotoxicity test, by combining it with bacterial repair enzyme FPG

  The alkaline comet assay, when employed as a genotoxicity test, has relatively low sensitivity because it fails to detect—at non-cytotoxic concentrations—known genotoxins that do not induce breaks or alkali-labile sites. We demonstrate that this limitation is overcome by incorporating in the assay more

• The first antibody therapy for cancer: a personal experience

  More than 100 years ago, Paul Ehrlich proposed that antibodies could be used for therapeutic purposes. Little progress was achieved until Köhler and Milstein developed hybridoma technology in the 1970s. In 1997, rituximab, the first antibody for the treatment of cancer, was approved. Its development more

• Dual control of Shuanghuang Shengbai granule on upstream and downstream signal modulators of CyclinD-CDK4/6 signaling pathway of cell cycle in Lewis-bearing mice with cyclophos ...

  Gu X, Xu Z, Zhu LY, Wang L, Li K, Pei Q more

Market studies Cyclophosphamide

• Brentuximab Vedotin – First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)

  Introduction The group of cancers that originate in the lymphatic system are known as lymphoma. Lymphoma is broadly classified into two types: Hodgkin lymphoma and non-Hodgkin lymphoma. In 2010, more than 16,887 new cases of Hodgkin lymphoma and 139,507 new cases of non-Hodgkin lymphoma were diagno more

• Brentuximab Vedotin – First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)

  Introduction The group of cancers that originate in the lymphatic system are known as lymphoma. Lymphoma is broadly classified into two types: Hodgkin lymphoma and non-Hodgkin lymphoma. In 2010, more than 16,887 new cases of Hodgkin lymphoma and 139,507 new cases of non-Hodgkin lymphoma were diagno more

Websites Cyclophosphamide